2-溴-5-氰基-4-甲基吡啶 | 1003711-35-0

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-溴-5-氰基-4-甲基吡啶
• 中文别名: 6-溴-4-甲基吡啶-3-甲腈
• 英文名称: 6-bromo-4-methylnicotinonitrile
• 英文别名: 2-Bromo-5-cyano-4-picoline；6-bromo-4-methylpyridine-3-carbonitrile
• CAS: 1003711-35-0
• 化学式: C₇H₅BrN₂
• 分子量: 197.034
• InChiKey: DHUDYHHQMIRPHS-UHFFFAOYSA-N

物化性质

• 沸点：
  288℃
• 密度：
  1.61
• 闪点：
  128℃

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  36.7
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Bromo-5-cyano-4-picoline
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Bromo-5-cyano-4-picoline
CAS number: 1003711-35-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H5BrN2
Molecular weight: 197

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

简介 6-溴-4-甲基吡啶-3-甲腈是一种医药中间体，文献报道其可用于制备PDE4抑制剂和ROMK通道抑制剂。

应用 6-溴-4-甲基吡啶-3-甲腈可用来合成具有取代含氮杂环结构的ROMK通道活性抑制剂。多项研究显示，ROMK通道活性的抑制能导致尿钠排泄增加、利尿效果增强以及血压下降。因此，在高血压、充血性心力衰竭或其他水肿性疾病患者中使用ROMK抑制剂，可以提供一种新的血压调控和利尿机制。

反应信息

• 作为反应物：
  描述：

  2-溴-5-氰基-4-甲基吡啶 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 lithium hydroxide monohydrate 、 水 、 三乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 20.0~70.0 ℃ 、6.67 kPa 条件下， 反应 21.0h， 生成 4-methyl-5-cyano-pyridine-2-carboxylic acid
  参考文献：
  名称：

  WO2021007477A5

  摘要：

  公开号：

  WO2021007477A5

文献信息

• Design, synthesis and evaluation of novel 5-phenylpyridin-2(1H)-one derivatives as potent reversible Bruton’s tyrosine kinase inhibitors
  作者：Xinge Zhao、Minhang Xin、Wei Huang、Yanliang Ren、Qiu Jin、Feng Tang、Hailong Jiang、Yazhou Wang、Jie Yang、Shifu Mo、Hua Xiang

  DOI：10.1016/j.bmc.2014.11.006

  日期：2015.1

  A series of novel reversible Btk inhibitors has been designed based on the structure of the recently reported preclinical drug RN486. The synthesis and SAR of these compounds are described. Among these derivatives, compound 16b was identified to be a potent and orally available reversible agent with satisfactory Btk enzymatic and cellular inhibition in vitro, as well as favorable PK properties and

  根据最近报告的临床前药物RN486的结构设计了一系列新型可逆性Btk抑制剂。描述了这些化合物的合成和SAR。在这些衍生物中，化合物16b被确定为有效的口服可逆剂，在体外具有令人满意的Btk酶和细胞抑制作用，在体内具有良好的PK特性和对关节炎的抑制作用。
• [EN] SUBSTITUTED NITROGEN CONTAINING COMPOUNDS<br/>[FR] COMPOSÉS CONTENANT DE L'AZOTE SUBSTITUÉ
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2018222795A1

  公开（公告）日：2018-12-06

  Disclosed are compounds of Formula (I): or a salt thereof, Formula (II) wherein R1 is: or; each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3a, R3b, L1, B, V, Y, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

  揭示了以下式（I）的化合物或其盐，式（II）其中R1是：或；每个W独立地是NR1b或O；Z是键或CHR1d；以及R1、R2、Rd、R3a、R3b、L1、B、V、Y和n在此处被定义。还揭示了将这些化合物用作ROMK抑制剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗心血管疾病方面是有用的。
• [EN] BICYCLIC AMINES AS NOVEL JAK KINASE INHIBITORS<br/>[FR] AMINES BICYCLIQUES UTILISÉS EN TANT QUE NOUVEAUX INHIBITEURS DE KINASE JAK
  申请人：LEO PHARMA AS

  公开号：WO2018134352A1

  公开（公告）日：2018-07-26

  The present invention relates to a compound according to formula (I) wherein R1 represents alkyl; n is 1 or 2; R2 is selected from the group consisting of hydrogen, cyano, -SO2Ra, -SO2NRbRc, –C(O)Rb, phenyl and 5-and 6-membered heteroaryl or pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention relates further to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

  本发明涉及一种化合物，其化学式为（I），其中R1代表烷基；n为1或2；R2选自氢，氰基，-SO2Ra，-SO2NRbRc，-C（O）Rb，苯基和5-和6-成员杂环基或其药用可接受盐、水合物或溶剂化合物。该发明进一步涉及上述化合物在治疗中的应用，包括含有该化合物的药物组合物，用于用该化合物治疗疾病的方法，以及用该化合物制造药品的用途。
• [EN] INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL<br/>[FR] INHIBITEURS DU CANAL POTASSIQUE MÉDULLAIRE EXTERNE RÉNAL
  申请人：MERCK SHARP & DOHME

  公开号：WO2015017305A1

  公开（公告）日：2015-02-05

  The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

  本发明提供了式I的化合物及其药学上可接受的盐，这些化合物是ROMK（Kir1.1）通道的抑制剂。这些化合物可用作利尿剂和/或钠利尿剂，并用于治疗和预防包括高血压、心力衰竭和慢性肾病在内的心血管疾病以及与过多盐分和水分潴留有关的疾病。
• Process for Preparing 1-Halo-2,7-Naphthyridinyl Derivatives
  申请人：Tyrrell Nicholas David

  公开号：US20090221828A1

  公开（公告）日：2009-09-03

  A process for preparing 1-halo-2,7-naphthyridinyl derivatives is described (I), wherein X is Cl or Br; which process comprises the following steps: (i) reaction of a 3-cyano-4-methylpyridine derivative of formula (A): with a compound of formula (II), in the presence of an N,N-dimethylformamide diC 1-6 alkylacetal; to give an enamine derivative of formula (III), (ii) cyclisation of the enamine of formula (III), to obtain the compound of formula (IV), (iii) reaction of the compound of formula (IV) with a halogenating agent, to obtain a compound of formula (I).

  本发明涉及一种制备1-卤代-2,7-萘啶衍生物的方法（I），其中X为Cl或Br；该方法包括以下步骤：（i）将式（A）的3-氰基-4-甲基吡啶衍生物与式（II）的化合物在N，N-二甲基甲酰胺二C1-6烷基缩醛的存在下反应，得到式（III）的恩酰衍生物；（ii）将式（III）的恩酰衍生物环化，得到式（IV）的化合物；（iii）将式（IV）的化合物与卤化剂反应，得到式（I）的化合物。